Main Article Content

Abstract

Background. Leptin is recognized as a cytokine-like hormone with pleiotropic actions in modulating immune responses. The role of leptin in pathogenesis of systemic
lupus erythematosus (SLE) was not fully understood yet. Previous study did not fi nd the correlation between serum leptin concentration and disease activity in patients with SLE, but selection of the subjects wasn’t based on the classifi cation of body mass index (BMI) and menopausal status.

Objective. To determine correlation between serum leptin concentration and the disease activity in normal BMI premenopausal women with SLE.

Methods. Serum leptin concentration was measured by enzyme-linked immunosorbent assay and disease activity was scored using Mexican SLE disease activity index (Mex-SLEDAI). Spearman’s correlation coeffi cient test was used for evaluating the strength of association between leptin level and Mex-SLEDAI score.
Results. Seventy normal BMI premenopausal women with SLE were included in this study. The median of serum leptin concentration was 13.4 (0.6 – 45.9) ng/ml.
The median serum leptin concentration in patients with active disease was 12.4 (0.6 – 41.6) ng/dl, whereas in patients with inactive disease was 15.2 (3.9 – 45.9) ng/dl.
No signifi cant different was found between serum leptin concentration in active and inactive disease (p = 0.14). A weak negative correlation was observed between leptin
concentration and Mex-SLEDAI score, but not statistically signifi cant (r = -0.22; p = 0.07).

Conclusion. No correlation was found between serum leptin concentration and disease activity in normal BMI premenopausal women with SLE. Prednisone doses and
disease duration might interfere.

Article Details

How to Cite
Suarjana, I. N., Kasjmir, Y. I., Isbagio, H., & Soegondo, S. (2018). Correlation between serum leptin concentration and disease activity in normal body mass index premenopausal women with systemic lupus erythematosus. Indonesian Journal of Rheumatology, 1(1). https://doi.org/10.37275/ijr.v1i1.15

References

  1. Garcia-Gonzales A, Gonzales-Lopez L, Valera-Gonzales IC, Cardona- Munoz EG, Salazar-Paramo M, Gonzales-Ortiz M, et al. Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int 2002;22:138-141.
  2. Karmiris K, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as infl ammatory mediators in infl ammatory bowel disease. Infl amm Bowel Dis 2005;11:847-855.
  3. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodefi ciency of malnutrition. FASEB J 2001;15:2565-2571.
  4. Huising MO, Kruiswijk CP, Flik G. Phylogeny and evolution of class-I helical cytokines. J Endocrinol 2006;189:1-25.
  5. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol 2007;4(1):1- 13.
  6. Silva C, Isenberg DA. Aetiology and pathology of systemic lupus erythematosus. Hospt Pharm 2001;7:1-7.
  7. The Asia-Pacifi c perspective: Redefi ning obesity and its treatment. 2000.
  8. Hochberg MC. Updating the American College of Rheumatology revised criteria for classifi cation of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
  9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Roth-fi eld NF, et al. The 1982 revised criteria for the classifi cation of systemic lupus erythematosus. Arhtritis Rheum 1982;25:1271-1277.
  10. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19:1551-1558.
  11. Valencia-Flores M, Resendiz M, Castaňo VA, Santiago V, Campos RM, Sandino S, et al. Objective and subjective sleep disturbances in patients with systemic lupus erythematosus. Arhtritis Rheum 1999;42:2189-2193.
  12. Wislowska M, Rok M, stepien K, Kuklo-Kowalska A. Serum leptin in systemic lupus erythematosus. Rheumatol Int 2008;28:467-473.
  13. Mantzoros CS. The role of leptin in human obesity and disease: A review of current evidence. Ann Intern Med 1999;130:671-680.
  14. Udden J, Bjorntrorp P, Arner P, Barkeling B, Meurling L, Rossner S. Effects of glucocorticoids on leptin levels and eating behaviour in women. J Intern Med 2003;253:225-231.
  15. Tataranni PA, Pratley R, Maffei M, Ravussin E. Acute and prolonged administration of glucocorticoids (methylprednisolone) does not affect plasma leptin concentration in humans. Int Obes Relat Metab Disord 1997;21(4):327-330.
  16. Bokarewa M, Bokarew D,Hultgren O, Tarkowski A. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:952-956.
  17. Harle P, Sarzi-Puttini P, Cutolo M, Straub RH. No change of serum levels of leptin and adiponectin during anti-tumor necrosis factor antibody treatment with dalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:970-971.
  18. Teplan V, Schuck O, Stollopa M, Vitko S. Obesity and hyperhomocysteinaemia after kidney transplantation. Nephrol Dial Transplant 2003;18(suppl 5):v71-v73.
  19. Valencia-Flores M, Resendiz M, Castaňo VA, Santiago V, Campos RM, Sandino S, et al. Objective and subjective sleep disturbances in patients with systemic lupus erythematosus. Arhtritis Rheum 1999;42:2189-2193.
  20. Gayed M, Gordon C. Pregnancy and rheumatic diseases. Rheumatology 2007; 46: 1634-40.
  21. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481-490
  22. Manson JJ, Isenberg DA. The Pathogenesis of systemic lupus erythematosus. J Netherl Med 2003;61(11):343-346.
  23. Zhao Y, Sun R, You L, Gao C, Tian Z. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 2003;300:247-252.
  24. Kümpers P, Horn R, Brabant G, Woywodt A, Schiffer M, Haller H, Haubitz M. Serum leptin and ghrelin correlate with disease activity in ANCA-associated vasculitis. Rheumatol (oxford) 2008;47(4):387-389.
  25. Saraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet III DJ, et al. Multiple cytokines and acute infl ammation raise mouse leptin levels : potential role in infl ammatory anorexia. J Exp Med 1997;185:171-175.
  26. Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW. Markers of infl ammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005;64:1195-1198.
  27. Bokarewa M, Bokarew D, Hultgren O, Tarkowski A. Leptin consumption in the infl amed joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:952-956.
  28. Van der Helm-van Mil AHM, Van der Kooij SM, Allaart CF, Toes REM, Huizinga TWJ. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008;67:769–774.
  29. Necla B, Ozan O, Aysun B, Oguz S, Peyami C, Sevim G, et al. Leptin, soluble leptin receptor, and transforming growth factor-β1 levels in minimal change nephrotic syndrome. Pediatric Nephrol 2003;18(10):1009-1014.